2 ASX healthcare shares to buy that you've not heard of: expert

If you want to invest in a sector that people still need during economic downturns, here's a pair of small caps that might interest you.

| More on:
a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Healthcare is one of those industries that enjoys relatively stable demand through tougher economic times.

With consecutive interest rises forcing Australians to close their wallets, this might be a consideration for the coming period.

But of course, the well-known ASX shares in the sector are already well bought.

So one Wilson Asset Management analyst has dug deeper into his research to come up with a couple of buys that are not yet household names:

'This company can re-rate over the next few years'

Probiotec Limited (ASX: PBP) only has a market capitalisation of $180 million. 

But for such a small cap it has managed to hold its stock price pretty well in 2022, only down 1.76% so far.

Wilson senior equity analyst Sam Koch is buying the pharmaceutical manufacturer and distributor.

"We believe the stock offers investors valuation and earnings upside," he said in a Wilson video.

"What the market's missing here is their ability to compound earnings growth at a very high rate, relative to its current valuation."

The business' "strong organic growth" is accompanied by bolt-on acquisitions, he added.

"Trading at 10 times P/E with over 15% [earnings per share] growth projected, we believe that this company can re-rate over the next few years."

While coverage is sparse on Probiotec, at least Shaw and Partners currently agrees with Koch, rating the stock as a strong buy.

Probiotec hands out a 2.5% dividend yield.

Share price now below PE ratio of ONE

CogState Limited (ASX: CGS) is arguably a technology business in addition to its involvement in the health sector.

That's because it's a cognitive science company that provides tech and services to biotechnology and pharmaceutical clients conducting clinical trials.

Koch said that big pharma relies on CogState's technology for their studies into Alzheimer's Disease.

"What we're really attracted to in CogState is that they were one of the first companies to provide the software-first technology, which has accelerated the industry's push towards decentralised clinical trials."

The value of CogState's services was recognised in one of its largest clients actually taking a 7% shareholding, according to Koch.

"The company's trading at below one times earnings-to-price growth multiple with over 15% of the market cap caught up in cash," he said.

"We believe that acquisitions and earnings upgrades will drive the stock from here."

According to CMC Markets, three of four analysts currently rate the stock as a strong buy.

The CogState share price has dropped more than 19% so far this year.

Motley Fool contributor Tony Yoo has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CogState Limited and Probiotec Limited. The Motley Fool Australia has positions in and has recommended CogState Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

Health professional putting on gloves.
Earnings Results

Why this ASX 200 share is soaring in Monday's sinking market

The ASX 200 share is shrugging off the broader market fall today to rocket higher. But why?

Read more »

Three Archer Materials scientists wearing white coats and blue gloves dance together in their lab after making a discovery
Healthcare Shares

Why is the Sigma share price soaring 6%?

Sigma has upgraded its FY25 guidance ahead of the anticipated Chemist Warehouse merger completion.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Which ASX 200 healthcare share will pay the best dividend yield in 2025?

Earnings season is underway and dividend announcements are on investors' minds.

Read more »

A person is weighed down by a huge stack of coins, they have received a big dividend payout.
Dividend Investing

Looking to bag the record high ResMed dividend? You better hurry!

Unlike the majority of ASX 200 income stocks, ResMed pays dividends every quarter.

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 reasons to buy CSL shares today

Two investment experts expect a big turnaround for CSL shares in 2025.

Read more »

Business people discussing project on digital tablet.
Healthcare Shares

Down 4%, is the ResMed share price in the buy zone?

Do analysts think investors should be buying the dip? Let's see what they are saying.

Read more »

A man holds his head in his hands, despairing at the bad result he's reading on his computer.
Healthcare Shares

Guess which ASX 100 share is sinking 8% because of Trump's tariffs

Donald Trump has dealt this company a big blow. What's happening?

Read more »